Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13075-017-1416-8 http://scihub22266oqcxt.onion/10.1186/s13075-017-1416-8 C5603046!5603046!28915838     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arthritis+Res+Ther 2017 ; 19 (ä): ä Nephropedia Template TP {{tp|p=28915838|t=2017. Gout and comorbidity: a nominal group study of people with gout |pdf=|usr=}}{{28915838}} gab.com Text Gout and comorbidity: a nominal group study of people with gout JO: Arthritis Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=28915838 #FOAvip Background: Comorbidities are common in patients with gout, yet qualitative research is lacking. The study objective was to examine the impact of gout on comorbidities. Methods: Nine nominal groups were conducted. Patients with gout discussed and rank-ordered their concerns in response to the question, ?How does gout or its treatment affect your other conditions and their treatment?? Results: Nine nominal groups had 45 gout patients, with mean age 61 years (standard deviation (SD) 10.7) and mean gout duration 14.9 years (SD 12). Of these, 62% were men, 45% African-American, 51% married and 63% were currently using allopurinol. The most frequently cited highly ranked concerns among the nine nominal groups were: (1) interaction of gout medication with medications for other medical conditions (three groups); (2) worsening of other medical comorbidities, including hospitalizations (seven groups); (3) worsening of anxiety and depression (three groups); (4) significant dietary changes for gout that contrasted with diet for other conditions (three groups); (5) new diseases diagnosed due to gout (three groups); (6) irreversible joint damage (three groups); (7) inability to exercise and weight gain (four groups); and (8) gout misdiagnosed as another health condition (three groups). Other domains ranked highly were: (1) impact of gout on daily life and activities, including the ability to work and social activities (six groups); (2) medication side effects, real and perceived (nine groups); (3) weight loss due to gout related to frequent flares (one group); and (4) cost and burden (three groups). Conclusions: Gout and the medications used for its treatment have a significant effect on comorbidities and their management. These findings provide insights into potential targets for improving outcomes in patients with gout. Twit Text FOAVip Gout and comorbidity: a nominal group study of people with gout ????Arthritis Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=28915838 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28915838 #FOAvip English Wikipedia <ref>{{Cite pmid|28915838}}</ref> Gout and comorbidity: a nominal group study of people with gout #MMPMID28915838 Singh JA Arthritis Res Ther 2017[]; 19 (ä): ä PMID28915838show ga Background: Comorbidities are common in patients with gout, yet qualitative research is lacking. The study objective was to examine the impact of gout on comorbidities. Methods: Nine nominal groups were conducted. Patients with gout discussed and rank-ordered their concerns in response to the question, ?How does gout or its treatment affect your other conditions and their treatment?? Results: Nine nominal groups had 45 gout patients, with mean age 61 years (standard deviation (SD) 10.7) and mean gout duration 14.9 years (SD 12). Of these, 62% were men, 45% African-American, 51% married and 63% were currently using allopurinol. The most frequently cited highly ranked concerns among the nine nominal groups were: (1) interaction of gout medication with medications for other medical conditions (three groups); (2) worsening of other medical comorbidities, including hospitalizations (seven groups); (3) worsening of anxiety and depression (three groups); (4) significant dietary changes for gout that contrasted with diet for other conditions (three groups); (5) new diseases diagnosed due to gout (three groups); (6) irreversible joint damage (three groups); (7) inability to exercise and weight gain (four groups); and (8) gout misdiagnosed as another health condition (three groups). Other domains ranked highly were: (1) impact of gout on daily life and activities, including the ability to work and social activities (six groups); (2) medication side effects, real and perceived (nine groups); (3) weight loss due to gout related to frequent flares (one group); and (4) cost and burden (three groups). Conclusions: Gout and the medications used for its treatment have a significant effect on comorbidities and their management. These findings provide insights into potential targets for improving outcomes in patients with gout. äGout and comorbidity: a nominal group study of people with gout (epmc).pdf DeepDyve Pubget Overpricing